Clinical Trials

A failed clinical trial for Zynerba Pharmaceuticals Inc.’s cannabidiol gel in adult epilepsy sent its stock plummeting 58.5% in heavy morning trade Monday. But the results could reflect well on rival GW Pharmaceuticals PLC GWPH, -2.13%  , a U.K.-based biopharma company that develops cannabinoid medications, said Leerink Partners analyst Paul Matteis. GW Pharma shares surged […]

by

A failed clinical trial for Zynerba Pharmaceuticals Inc.’s cannabidiol gel in adult epilepsy sent its stock plummeting 58.5% in heavy morning trade Monday. But the results could reflect well on rival GW Pharmaceuticals PLC GWPH, -2.13%  , a U.K.-based biopharma company that develops cannabinoid medications, said Leerink Partners analyst Paul Matteis. GW Pharma shares surged […]

by

SAN DIEGO, Aug. 3, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a […]

by

JERUSALEM, August 3, 2017 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pillâ„¢ platform technology, announces the results from a Phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with cannabidiol (CBD) and tetrahydrocannabinol (THC), the two primary cannabinoids […]

by

“We’re excited about these encouraging results from our Phase 1 study of AP-CBD/THC as it shows the Accordion Pill platform is well suited to safely deliver CBD and THC with significant improvements in exposure compared with Sativex®,” said Nadav Navon, Ph.D., Chief Operating Officer of Intec Pharma. “We are particularly pleased to see the reduction […]

by

NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a clinical trial with its CanChew Plus® cannabidiol (CBD) chewing gum […]

by

Roberto and Maria’s 13-year-old daughter has Dravet syndrome which causes many severe seizures daily. But with the help of a cannabis compound, she’s been nearly seizure free.  It’s bed time for 13-year-old Viridiana. And as her parents, Roberto and Maria, read to her, they know their daughter’s own story is different than a normal child’s. […]

by

DEVON, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today reported financial results for the second quarter ended June 30, 2017 and provided an overview of recent operational highlights. “We expect to announce top-line results from the […]

by

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a nano-cap specialty pharmaceutical company that specializes in transdermal synthetic cannabinoid treatments for patients with high unmet needs, reported its second-quarter results Tuesday and also provided several key updates to ongoing clinical trials. Q2 Results Zynerba said it lost $0.64 per share in the second quarter on zero […]

by

DEVON, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today reported financial results for the second quarter ended June 30, 2017 and provided an overview of recent operational highlights. “We expect to announce top-line results from the […]

by

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a nano-cap specialty pharmaceutical company that specializes in transdermal synthetic cannabinoid treatments for patients with high unmet needs, reported its second-quarter results Tuesday and also provided several key updates to ongoing clinical trials. Q2 Results Zynerba said it lost $0.64 per share in the second quarter on zero […]

by